Pricing Log in Create free account
Saturday 17 October 2026 Export HYPR’s income statement to Excel — free account

Hyperfine, Inc.

HYPR Healthcare Medical Devices

Hyperfine, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $13.6 million, up 5.22% from fiscal 2024. In the quarter to June 2026, revenue grew 44.8%, EPS grew 25.0% and free cash flow grew 13.4%, each against the same quarter a year earlier. Revenue growth for five consecutive years, operating cash flow growth for three.

0.75 0.03 −3.85%
Market cap
$82.7M
P/E
0.0×
Fwd P/E
−4.0×
Dividend yield
—
F-score
4/9
Altman Z
−6.11
Beneish M
−3.54
Dividend safety
n/a
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 0.09
Totals in millions of $.
Dec 25 Mar 26 Jun 26 Sep 26
Buy — — — — — — — — — — — —
Sell 1 — — 1 2 — 2 — — 2 — —
Insider Ownership 14.87%

Capital & Financial Ratios $m

Market Cap 82.73
Revenue 16.54
Net Income (34.85)
Free Cash Flow (27.53)
Net Debt (31.53)
Current Ratio 6.15 (at or above 1.5: strong)
Debt/Equity 0.36 (at or below 0.5: strong)
P/E ratio 0.00
Fwd P/E (3.98) (negative: loss-making)
P/S ratio 4.53
P/B ratio 2.04
Past 5Y EPS Growth —
This Y EPS Growth 20.93% (at or above 15%: strong)
Next Y EPS Growth 5.88%
Next Y revenue growth 49.16% (at or above 10%: strong)
Next 5Y EPS Growth 11.31%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 2.6×, against a ten-year median of 2.1×; over the ten years it ranged from −119× in 2022 to 31.9× in 2022.
P/S against its own 10 years 2.91%
10-year low 10-year high
P/B against its own 10 years 64.75%
10-year low 10-year high
EV/Sales against its own 10 years 38.61%
10-year low 10-year high

Dividends

Payout Ratio —
Annual Dividend Rate —
Annual Dividend Yield —

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 76 38 36 45
Receivables 4 8 7 6
Inventory 7 6 7 7
Other — — — —
89 54 51 59
2023 2024 2025 Q'26
Payables 1 2 4 2
ST’ Debt — — — —
Other 1 0 1 1
9 9 12 10

Compound Annual Growth %

10y 5y 3y
Sales — 115.18% 25.79%
Cash Flow — 0.00% 0.00%
Earnings — 0.00% 0.00%
Book Value — 0.00% (30.80%)

Revenue $m

Mar Jun Sep Dec Year
’26 4 4 — — —
’25 2 3 3 5 14
’24 3 4 4 2 13
’23 3 3 2 3 11
’22 2 2 2 1 7
’21 0 0 0 0 1
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 (9) (7) — — —
’25 (9) (8) (6) (5) (28)
’24 (13) (9) (9) (8) (39)
’23 (13) (10) (9) (10) (42)
’22 (27) (17) (13) (15) (72)
’21 (7) (12) (10) (18) (47)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (9) (7) — — —
’25 (10) (8) (6) (5) (29)
’24 (13) (9) (9) (8) (39)
’23 (14) (10) (9) (10) (43)
’22 (28) (17) (13) (16) (73)
’21 (8) (12) (11) (19) (50)
Fiscal quarters ending in the months shown.

EPS $

Mar Jun Sep Dec Year
’26 (0.09) (0.09) — — —
’25 (0.12) (0.12) (0.14) (0.06) (0.43)
’24 (0.14) (0.14) (0.14) (0.14) (0.56)
’23 (0.17) (0.15) (0.15) (0.15) (0.62)
’22 (0.34) (0.33) (0.19) (0.19) (1.04)
’21 (4.86) (8.80) (8.66) (2.73) (17.57)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 Trend 2026e 2027e 2028e
Price, $
Price, $ Low — — — — — 6.85 0.68 0.77 0.76 0.53

Analyst estimates 2026–2028

Powerpack
High — — — — — 16.61 7.50 3.28 1.39 2.22
People
People Employees — — — — 2 193 136 131 111 102
Revenue/emp, $m — — — — 0.15 0.01 0.05 0.08 0.12 0.13
Income, $m
Income, $m Revenue — — — — 0 1 7 11 13 14
Gross margin, % — — — — (162.24) (78.01) 13.31 43.12 45.70 49.79
EBT — — — — (23) (65) (73) (44) (41) (36)
EBT margin, % — — — — (7,968.37) (4,334.96) (1,073.73) (401.00) (315.90) (262.29)
Net income — 0 — — (23) (65) (73) (44) (41) (36)
Depreciation — — — — 0 1 1 1 1 1
Per share, $
Per share, $ Revenue — — — — 0.19 0.41 0.10 0.15 0.18 0.17
Earnings — — — — (15.38) (17.57) (1.04) (0.62) (0.56) (0.43)
Cash flow — — — — (14.13) (12.78) (1.03) (0.59) (0.54) (0.34)
Capex — — — — (1.03) (0.73) (0.01) (0.01) (0.01) (0.01)
Free cash flow — — — — (15.16) (13.52) (1.04) (0.60) (0.54) (0.36)
Book value — — — — (40.09) 50.45 1.76 1.18 0.68 0.50
Shares, m — — — — 2 4 70 71 72 82
Valuation, ×
Valuation, × P/E — — — — 0.00 0.00 0.00 0.00 0.00 0.00
P/S — — — — 0.00 17.89 8.58 7.30 4.94 5.91
P/B — — — — 12,839.40 0.14 0.47 0.95 1.30 1.95
EV/Sales — — — — 0.00 (109.89) (8.77) 0.43 2.02 3.25
EV/FCF — — — — 0.00 3.30 0.82 (0.11) (0.67) (1.51)
Cash, $m
Cash, $m Operating cash flow — — — — (22) (47) (72) (42) (39) (28)
Capex — — — — (2) (3) (1) (1) 0 (1)
Free cash flow — — — — (23) (50) (73) (43) (39) (29)
Balance, $m
Balance, $m Working capital — — — — 64 182 120 80 45 39
Total debt — — — — 0 — — — — —
Net debt — — — — (64) (191) (118) (76) (38) (36)
Shareholders’ equity — — — — (61) 186 124 84 49 41
Returns, %
Returns, % ROA — — — — (65.51) (47.34) (43.48) (38.76) (53.19) (62.32)
ROIC — — — — 0.00 0.00 (842.69) (349.88) (237.66) (467.02)
ROE — — — — (37.43) (103.62) (47.21) (42.51) (61.03) (79.01)
Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Hyperfine, Inc. vs peers in Medical Devices (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
APYX Apyx Medical Corporation $107.8M — (loss-making) — (loss-making) +22.08% (above 0%: growing) n/m −137.38% (below 0%: shrinking) 63.89% (13.01%) Compare
LUCD Lucid Diagnostics Inc. $105.7M — (loss-making) — (loss-making) +26.74% (above 0%: growing) n/m −7.04% (below 0%: shrinking) 1.97% (868.45%) Compare
ZOMDF Zomedica Corp. $95.4M — (loss-making) — (loss-making) +36.59% (above 0%: growing) n/m +40.48% (above 0%: growing) 63.51% (42.92%) Compare
HYPR Hyperfine, Inc. $82.7M — (loss-making) — (loss-making) +44.81% (above 0%: growing) n/m +13.43% (above 0%: growing) 50.72% (216.93%)
SERA Sera Prognostics, Inc. $80.1M — (loss-making) — (loss-making) +76.47% (above 0%: growing) n/m −10.58% (below 0%: shrinking) (66.67%) (33,346.67%) Compare
LUNG Pulmonx Corporation $79.5M — (loss-making) — (loss-making) −4.62% (below 0%: shrinking) n/m −31.79% (below 0%: shrinking) 77.97% (39.80%) Compare
OM Outset Medical, Inc. $76.6M — (loss-making) — (loss-making) +0.69% (above 0%: growing) n/m −90.54% (below 0%: shrinking) 41.99% (49.55%) Compare
ECOR electroCore, Inc. $75.3M — (loss-making) — (loss-making) +28.03% (above 0%: growing) n/m −443.52% (below 0%: shrinking) 86.53% (29.33%) Compare
LNSR LENSAR, Inc. $74.1M 2.0× 7.1× +18.37% (above 0%: growing) n/m +96.81% (above 0%: growing) 59.27% 12.94% Compare
Median of peers $79.8M — — +24.41% — −21.18% 61.39% (41.36%)

All 149 Medical Devices stocks →

Hyperfine, Inc. (HYPR) key facts

  • Strength: Hyperfine, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $13.6 million, up 5.22% from fiscal 2024.
  • Hyperfine, Inc. (HYPR) is a Medical Devices company in the Healthcare sector, listed on Nasdaq.
  • As of October 16, 2026, HYPR traded at $0.75, a market capitalization of $82.7 million.
  • Return on equity was −79.0% and debt-to-equity 0.36.
  • Its Piotroski F-score is 4 out of 9 and its Altman Z-score is −6.11 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.

Hyperfine, Inc. (HYPR) Latest News

No news at this impact. Lower the threshold for more.
stockrow.com/HYPR · Data as of Jun 30, 2026 · For information only; not investment advice. · © 2026 stockrow.com